TO THE EDITOR: I read with interest the essay by Agrawal (1) . Being a gay man with a life partner of more than 13 years, I've had similar encounters and awkward situations that have caused similar internal struggles on many levels. When I was confronted by a colleague who said I still had internalized homophobia, I was incredulous. After discussing it, however, I agreed that he was probably correct in his assessment. Part of the coming-out process is overcoming the shame of being different and always expecting to be judged negatively by any newcomer one comes across. The difficulty in sharing the truth of a nontraditional relationship is all in the context. Clearly, with Dr. Agrawal's story, telling the truth would have been awkward because the patient was already in an exposed situation that could have gone badly in a heartbeat. Changing gender and examination, the same awkwardness could be found if it somehow came out during a prostate examination that the health care provider was a gay man. If there is really any worry, then having a chaperone always helps to diffuse things like that.
Sure, Dr. Agrawal missed a chance to be truthful. And, in time, I've had to correct some people's misconceptions. I feel that it boils down to a transference reaction on the part of the patient that can detract from the clinical role at hand. I don't volunteer much because I find it's a distraction that erodes the time needed to deal with a number of complicated medical problems. If patients ask, I remind them that I have a fiduciary responsibility to focus on them, not me. One can argue that the patients are looking for cues that will help them feel comfortable with me. I try to accomplish this by clarifying their medical conditions, medications, laboratory reports; but not my personal life. When the issue does come up, it's usually been the question, "Do you have any children?" I politely respond that my partner and I don't have any children, but that we do have 2 basset hounds and a Moluccan cockatoo, and I thank them for asking.
It's an interesting balancing act, to say the least. IN RESPONSE: I agree that physicians must be truthful to earn the trust of their patients, and that trust is the bedrock of a healthy physician-patient relationship. This is precisely the reason for my distress with the patient interaction I described. However, the issue of patient and physician perception in regard to sexual orientation is complicated. A 1994 national survey of gay and lesbian physicians revealed that 67% felt they "would jeopardize their practices if their colleagues learned they are lesbian, gay, or bisexual" and 75% felt they "would jeopardize their practices if their patients learned they are lesbian, gay, or bisexual" (1).
At least 2 further studies of patients' attitudes on this issue seem to support this apprehension on the part of physicians. Lee and colleagues (2) found that many of the 502 patient respondents in a national survey indicated that they would change health care providers if they found out their provider was gay or lesbian (30.4%) or would change practices if gay or lesbian providers were employed there (35.4%). Another study, published in 1998, found that 11.8% of respondents would refuse to see a gay or lesbian physician, the most common reasons being fears of incompetence and worries about feeling "uncomfortable" (3).
Estimates suggest that several hundred thousand gay or lesbian providers practice in the United States. Therefore, this issue can affect many patients, families, and their providers. I hope my essay, your letters, a continuing dialogue, and further studies will foster greater understanding among patients, physicians, communities, and society in regard to this issue.
Abha Agrawal, MD Kings County Hospital Center Brooklyn, NY 11203
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TO THE EDITOR:
In reviewing the findings of Cavanaugh and colleagues (1), we were impressed that the association between low numeracy and poor glycemic control seemed much stronger among insulin users than among persons taking oral medications. In addition, their finding that insulin users with low numeracy were less likely than those with high numeracy to self-adjust insulin dosage and count carbohydrates provides a possible mechanism. This would suggest that not only does numeracy affect quality, it may also have important implications for patient safety. Hypoglycemia relating to insulin use is a leading cause of adverse drug events resulting in emergency department visits (2), and we have found that patients with diabetes who report having problems learning about their health because of reading difficulties have higher incidences of severe hypoglycemia episodes (3). Taken together, this research suggests that system-level interventions to mitigate the effects of limited literacy and low numeracy must involve some combination of adequate self-management support regarding insulin use, individualized glycemic targets, and proactive surveillance (4) 
IN RESPONSE:
We agree that interventions to reduce the frequency and severity of hypoglycemic episodes in patients are an integral component of diabetes care and patient safety. Patient literacy and numeracy may play an important role in adverse events related to blood sugar management. For a subgroup of patients in our study (n ϭ 163 [41% of the primary sample]), we were able to download data from their blood glucose meters and obtain information about the frequency of hypoglycemic events (defined as blood glucose level Ͻ3.33 mmol/L [Ͻ60 mg/dL]) and the proportion of blood glucose measures less than 3.89 mmol/L (Ͻ70 mg/dL). Most of these patients (58%) did not have a measured hypoglycemia event; however, 42% recorded at least 1 event, and 10% of these patients had more than 5 events recorded. Although patients with type 1 diabetes (n ϭ 42) were more likely to have hypoglycemic events than patients with type 2 diabetes (n ϭ 121) (86% vs. 27%; P Ͻ 0.001), neither health literacy nor diabetes-related numeracy was associated with the number of hypoglycemic events as measured by self-monitoring of blood glucose levels in patients with either type of diabetes. Health literacy or diabetes-related numeracy was also not found to be statistically significantly associated with a proportion of blood glucose meter readings that were low (Ͻ3.89 mmol/L [Ͻ70 mg/dL]). Results were also similar if patients using only insulin (n ϭ 121) were included in the analysis. This subgroup evaluation was limited by its small, selected sample of patients, and it was not adequately powered to evaluate this important question. Patients with lower numeracy may have had higher rates of hypoglycemic episodes but did not record these episodes with their glucose meter or did not bring their meter to clinic for download. Additional, larger studies are needed to define the role of literacy and numeracy in the prevention of serious adverse events and overall safety of patients with diabetes and other chronic diseases.
Objective: To describe a case of disseminated histoplasmosis associated with treatment with adalimumab.
Case Report: A 41-year-old white man with rheumatoid arthritis, treated with adalimumab for 9 months, presented for evaluation of 3 weeks of worsening malaise and intermittent fevers. He did not report any joint pain, myalgias, or rash. He subsequently developed progressive dyspnea without cough or chest pain.
On physical examination, his temperature was 39.4°C, and he had tachycardia and tachypnea. His oxygen saturation was 94% on 3 L of oxygen by nasal cannula. He had scleral icterus but no lymphadenopathy. His lungs were clear to auscultation. He had no cardiac murmurs. His abdomen was distended, with marked, tender hepatosplenomegaly. Joint and skin examinations were normal. He had mild anemia and elevated serum transaminases. Chest radiography showed paratracheal lymphadenopathy, and chest computed tomography revealed bilateral upper lobe-predominant ground-glass opacities. Ultrasonography confirmed marked hepatosplenomegaly without ductal dilation.
On admission, adalimumab treatment was stopped and broadspectrum antibiotics initiated. Blood and urine cultures for routine bacteria and fungi were negative. We performed bronchoscopy with bronchoalveolar lavage, and bacterial and fungal stains and cultures as well as acid-fast staining were all initially negative. As the patient developed respiratory failure, we added amphotericin B. Further analysis of the bronchoalveolar lavage revealed histoplasmosis by DNA polymerase chain reaction. Urine subsequently tested positive for histoplasma antigen. Because the patient had developed pancytopenia, we performed bone marrow biopsy; it showed noncaseating granulomas consistent with histoplasmosis. The patient responded well to amphotericin B and, after 7 days, was transitioned to itraconazole therapy for 6 weeks. We then discontinued itraconazole treatment but planned to resume prophylactic itraconazole if the patient required further immunosuppressive rheumatoid arthritis treatment. We permanently discontinued adalimumab treatment.
Discussion: Therapy targeting inflammatory cytokines, such as TNF-␣, represents novel treatment for such diseases as rheumatoid arthritis but comes with increased risk for opportunistic infections (1). Tumor necrosis factor-␣ induces collagenase production by synovial macrophages, resulting in joint degradation; blocking this through anti-TNF agents leads to clinical improvement. Tumor necrosis factor-␣ is also important in host defense: It is essential in the cascade of inflammatory cytokines that cause granuloma formation, a necessary response for effective defense against histoplasma (2) .
Currently available anticytokine agents include etanercept, infliximab, and adalimumab. All have been associated with an increased risk for infection, particularly by pathogens cleared by a granulomatous response, but with important differences. Infliximab and adalimumab suppress interferon-␥ production, also needed for granuloma formation; this may further increase the risk for infection. Postlicensure reporting to the U.S. Food and Drug Administration indicates that disseminated histoplasmosis has occurred with greater frequency with infliximab than with etanercept. Given its similarities to infliximab, adalimumab, a newer agent with fewer reported cases of infection, is likely to have a higher incidence of granulomatous infection (3) .
Cases of histoplasmosis generally occur in the Mississippi River Valley (the patient lived in Branson, Missouri), and initial infection often remains latent until an immunocompromised state arises, at which time patients may present with vague symptoms, including fever, malaise, cough, and dyspnea. Diagnosis can be confirmed through fungal stains or culture of bronchoalveolar lavage or direct lung biopsy specimens, or by urine histoplasma antigen testing.
Because few cases of histoplasmosis in patients treated with TNF-␣ antagonists have been reported, prophylactic treatment or routine screening for histoplasmosis is not recommended. Providers caring for patients with rheumatoid arthritis should weigh the potential benefits of anticytokine therapy against the risk for infection for each patient (4) .
Conclusion: Treatment with adalimumab may increase risk for disseminated histoplasmosis in endemic areas. The patient had no family evidence or history of diabetes or glucose intolerance. Her body mass index was 23 kg/m 2 , and we noticed no weight gain during treatment.
Nina Saksena Asrani, MD
After discontinuation of clomipramine and metabolic compensation with intravenous insulin and fluids, she required regular insulin, 30 U/d. Her blood glucose levels rapidly normalized, and she was discharged 10 days later without insulin therapy and with a diabetic diet and psychological treatment.
The patient remained metabolically stable (hemoglobin A 1c level, 0.05). After 3 months and after she provided written informed consent, we reintroduced clomipramine under medical surveillance. One week later, the patient's fasting glucose level increased to 13.88 mmol/L (250 mg/dL) with glycosuria and ketonuria. Again, we discontinued clomipramine treatment, and the glycemia normalized in 2 days. She has been euglycemic without therapy for the past 6 months.
Discussion: It is well recognized that certain antipsychotic medications can cause clinically significant elevations in glucose concentration and an increased risk for obesity and the metabolic syndrome (1) .
Of recent interest are the increasing numbers of reported cases of new-onset diabetes in patients receiving treatment with atypical antipsychotic agents, such as clozapine (2) . In most cases, the mechanisms by which hyperglycemia occurs are not fully understood, although several possible theories have been proposed for this drug class (3).
We considered our patient's hyperglycemia to be induced by clomipramine because of the temporal relationship, the recurrence of glucose elevation with reintroduction of the drug, and the normalization of the glucose level after discontinuation of therapy with the drug. To our knowledge, there have been no previous reports of hyperglycemia associated with the use of clomipramine. Although clomipramine has not been reported to cause diabetes in humans, it can cause diabetes in mice: Sugimoto and colleagues (4) recently demonstrated that clomipramine induced hyperglycemia in mice by blocking the 5-hydroxytryptamine-2B or -2C receptor, which resulted in facilitation of adrenaline release.
Conclusion: Given these consequences of poor glycemic control, physicians should be aware of medications that may affect glucose metabolism. However, further studies with this drug are necessary before any conclusions can be made, and more data are needed to prove an association between clomipramine and diabetes. 
